PARAMUS, N.J., May 20, 2024 (GLOBE NEWSWIRE) — Starton Therapeutics Inc. (“Starton” or the “Company”), a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary dermal technologies, announced today that the U.S. Patent and Trademark Office (USPTO) granted US Patent # 11,975,112 for “Treatment of Vomiting and Nausea with Minimum Dose of Olanzapine”.
U.S. Patent and Trademark Office Grants US Patent # 11,975,112 for “Treatment of Vomiting and Nausea with Minimum Dose of Olanzapine”
Home »
U.S. Patent and Trademark Office Grants US Patent # 11,975,112 for “Treatment of Vomiting and Nausea with Minimum Dose of Olanzapine”
Ähnliche Beiträge
Trump Offloads Ebola-Infected American Citizen to Germany
Berlin/Washington (LabNews Media LLC) – A U.S. medical missionary infected with the Bundibugyo strain of Ebola virus disease (EVD) has been evacuated to Berlin’s Charité…
Kanada investiert 6,8 Millionen Dollar in KI-Projekte in Alberta
Edmonton (LabNews Media LLC) – Die kanadische Bundesregierung fördert fünf Projekte in Alberta mit insgesamt 6,8 Millionen Dollar über die Regional Artificial Intelligence Initiative (RAII).…
Ebola in Deutschland: Kaum Sonderisoliertstationen (SIS)
Berlin (LabNews Media LLC) – Die Weltgesundheitsorganisation (WHO) hat den Ebola-Ausbruch mit der Bundibugyo-Variante in der Demokratischen Republik Kongo und Uganda als internationale gesundheitliche Notlage…
